Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03899987CT.gov Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | — | Active Not Recruiting | — | — | — |
NCT03819101CT.gov Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT03103152CT.gov A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression | — | Completed | — | — | — |
NCT02757365CT.gov Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer | — | Unknown | — | — | — |
NCT00316927CT.gov Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00055731CT.gov Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aspirin (this asset) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Approved | BB · 66 |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BBB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BBB |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BB |
| Goserelin | Bayer | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Flutamide | VA Office of Research and Development | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Aspirin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 80 |
| Transient Ischemic Attack | — | P4 | BBB · 76 |
| Cerebral Infarction | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aspirin in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/aspirin-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →